Diagnostic Performance of Ultrasound vs Ultrasound-Guided FNAC in Thyroid Nodules: Data From the ElaTION Trial
The Journal of Clinical Endocrinology & Metabolism · 17.06.2025 · 110 (7) · 1997-2006
DOI: 10.1210/clinem/dgae682 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.10.2024. Verfasst von Hisham Mehanna und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Head and Neck Studies and Education (InHANSE), Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT,…. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms, Endoscopic Ultrasound-Guided Fine Needle Aspiration, Thyroid Gland. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institute for Health and Care Research, NIHR Health Technology Assessment programme.
Abstract (Originalsprache)
Introduction
ElaTION is a large multicenter pragmatic randomized controlled trial, performed in 18 secondary/tertiary hospitals across England, comparing elastography ultrasound-guided fine needle aspiration cytology (EUS-FNAC) with ultrasound-guided FNAC (US-FNAC) alone in the diagnostic assessment of thyroid nodules. Secondary trial outcomes, reported here, assessed the accuracy of ultrasound alone (US) compared with US-FNAC to inform and update current practice guidelines.
Methods
Adults with single or multiple thyroid nodules who had not undergone previous FNAC were eligible. Radiologists assessed all thyroid nodules using US alone, thereby enabling assessment of its accuracy (sensitivity and specificity) vs US-FNAC.
Results
Of the 982 participants, a final definitive diagnosis was obtained in 688, who were included in the final analyses. The sensitivity of US alone was the same as US-FNAC (0.91 [95% CI, 0.85-0.97] vs 0.87 [95% CI, 0.80-0.95] P = .37). US alone had statistically significant lower specificity than US-FNAC alone (0.48 vs 0.67 respectively, P < .0001). The malignancy rate on histology in a nodule classified as benign on ultrasound (U2) was 9/263 (3.42%) and on cytology (Thy2) was 15/353 (4.25%), whereas the malignancy rate in a nodule that was benign on both (U2, Thy2) was 3/210 (1.43%). Malignancy risk for U3, U4, and U5 nodules was 68/304 (22.4%), 43/83 (51.8%), and 29/38 (76.3%), respectively (P < .0001). Yet 80/982 (8%) patients were discharged despite having U3-U5 scans with Thy1 (nondiagnostic) FNAC and no definitive diagnosis. Malignancy risk was higher in smaller nodules: < 10 mm 23/60 (38.3%), 10-20 mm 46/162 (28.4%), and >20 mm 80/466 (17.2%) (P < .0001). Nodules with indeterminate cytology with atypical features (Thy3a) carried a similar malignancy risk to those with indeterminate cytology (Thy3/3f): 27/95 (28.4%) vs 42/113 (37.2%) respectively (P = .18).
Conclusion
Ultrasound alone appears to be an effective diagnostic modality in thyroid nodules, confirming the recommendations of recent guidelines and the British Thyroid Association classification. However, findings also suggest caution regarding existing recommendations for conservative management of nondiagnostic (Thy1/Bethesda I) and atypical (Thy3a/Bethesda III) nodules. In those cases, ultrasound (U3-U5) features may help identify high-risk subgroups for more proactive management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Head and Neck Studies and Education (InHANSE), Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, B15 2TT, UK.
- Institute of Applied Health Research, University of Birmingham, Birmingham, B15 2TT, UK.
- Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK.
- Department of Otolaryngology, Head and Neck Surgery, Queen Elizabeth Hospital Birmingham, Birmingham, B15 2TH, UK.
- Department of Imaging Sciences, School of Biomedical Engineering and Imaging Sciences, King's College London, London, SE17EH, UK.
- Department of Radiology, King's College Hospital NHS Foundation Trust, London, SE5 9RS, UK.
ORCID-Profile: Hisham Mehanna, Paul Nankivell, Kristien Boelaert, Rebecca Woolley, Neil Sharma, Paul S Sidhu
Förderung
- National Institute for Health and Care Research
- NIHR Health Technology Assessment programme
Zitieren
APA
Mehanna, H., Nankivell, P., Boelaert, K., Woolley, R., Sharma, N., Sidhu, P. S., Madani, G., Da Forno, P., Moreman, C., Palmer, A., Fulton-Lieuw, T., Taylor, J., Rajaguru, K., Bekker, J., Vaidhyanath, R., Rehman, T., & Deeks, J. (2025). Diagnostic Performance of Ultrasound vs Ultrasound-Guided FNAC in Thyroid Nodules: Data From the ElaTION Trial. The Journal of Clinical Endocrinology & Metabolism, 110(7), 1997-2006. https://doi.org/10.1210/clinem/dgae682
Vancouver
Mehanna H, Nankivell P, Boelaert K, Woolley R, Sharma N, Sidhu PS, et al. Diagnostic Performance of Ultrasound vs Ultrasound-Guided FNAC in Thyroid Nodules: Data From the ElaTION Trial. The Journal of Clinical Endocrinology & Metabolism. 2025;110(7):1997-2006. doi:10.1210/clinem/dgae682
BibTeX
@article{Mehanna2025,
author = {Mehanna, Hisham and Nankivell, Paul and Boelaert, Kristien and Woolley, Rebecca and Sharma, Neil and Sidhu, Paul S and Madani, Gitta and Da Forno, Philip and Moreman, Catherine and Palmer, Andrew and Fulton-Lieuw, Tessa and Taylor, Judith and Rajaguru, Kanchana and Bekker, Jasper and Vaidhyanath, Ram and Rehman, Thaj and Deeks, Jon},
title = {Diagnostic Performance of Ultrasound vs Ultrasound-Guided FNAC in Thyroid Nodules: Data From the ElaTION Trial},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
volume = {110},
number = {7},
pages = {1997--2006},
doi = {10.1210/clinem/dgae682}
}
EUVIMED